GBF Gesellschaft für Biotechnologische Forschung mbH, Braunschweig
Abstract
A liposome-based flow injection immunoassay (FIIA) system for quantitation ofa clinical analyte,
theophylline, and also, with very minor changes in the assay format, of an antibody to theophylline,
has been developed. Automated sequential analyses were performed at room temperaturewith
picomolesensitivity and a day-to-day coefficient of variation of less than 5 %. The system components
include liposomesthat contain fluorophoresin their aqueouscentral cavities and an
immobilized-antibody reactor column. The immunoreactor was regenerated hundreds of times
over three monthsof continuoususe with no measurable loss of antibody activity. The special
advantages ofusing flow injection analysis for immunoassays and ofusing liposomesin FIIA,
compared to most current immunoassay techniques,are described
